LoginSignup
TG Therapeutics logo

TG Therapeutics

Stock
Stock
ISIN: US88322Q1085
Ticker: TGTX
US88322Q1085
TGTX

Price

Price

Frequently asked questions

What is TG Therapeutics's market capitalization?

The market capitalization of TG Therapeutics is $4.85B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for TG Therapeutics?

TG Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.107. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for TG Therapeutics's stock?

Currently, 9 analysts cover TG Therapeutics's stock, with a consensus target price of $31.00. Analyst ratings provide insights into the stock's expected performance.

What is TG Therapeutics's revenue over the trailing twelve months?

Over the trailing twelve months, TG Therapeutics reported a revenue of $264.79M.

What is the EBITDA for TG Therapeutics?

TG Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $4.19M. EBITDA measures the company's overall financial performance.

What is the free cash flow of TG Therapeutics?

TG Therapeutics has a free cash flow of -$28.09M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of TG Therapeutics's stock?

The 5-year beta for TG Therapeutics is 2.20. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does TG Therapeutics have, and what sector and industry does it belong to?

TG Therapeutics employs approximately 319 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of TG Therapeutics's shares?

The free float of TG Therapeutics is 140.87M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $4.85B

5Y beta

 2.20

EPS (TTM)

 -$0.107

Free Float

 140.87M

Revenue (TTM)

 $264.79M

EBITDA (TTM)

 $4.19M

Free Cashflow (TTM)

 -$28.09M

Pricing

1D span
$30.95$36.45
52W span
$12.30$36.50

Analyst Ratings

The price target is $31.00 and the stock is covered by 9 analysts.

Buy

7

Hold

1

Sell

1

Information

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

319

Biotechnology & Drugs

Health Care

Identifier

ISIN

US88322Q1085

Primary Ticker

TGTX

Knockouts

Join the conversation
Sign upLogin